Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib
2
Real-World Data Analysis Highlight Clinical Profiles and Inebilizumab Use Patterns in NMOSD
3
Comparative Study Reveals Psychiatric Comorbidities Common in MOGAD, MS, and NMOSD, With Distinct Timing Patterns
4
NeurologyLive® Friday 5 — February 6, 2026
5